Revision of breast cancer staging: the 6th edition of the TNM Classification
- PMID: 12923916
- DOI: 10.1002/ssu.10021
Revision of breast cancer staging: the 6th edition of the TNM Classification
Abstract
A Breast Task Force comprised of nationally known experts in the field of breast cancer treatment was charged with recommending additions and changes for the 6th edition of the TNM Classification that were based on published evidence and/or were consistent with widespread clinical consensus. Additions made to the staging system were designed to facilitate the uniform collection of clinically relevant information about new techniques for the detection of metastatic cells. These additions include quantitative criteria to distinguish micrometastases from isolated tumor cells, and specific identifiers to record the use of sentinel lymph node biopsy, immunohistochemical (IHC) staining, and molecular biology techniques. Revisions of the previous staging system are related to the number of affected axillary lymph nodes and to the classification of level III axillary lymph nodes and lymph nodes outside of the axilla.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
[Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What's new for the pathologist?].Ann Pathol. 2003 Dec;23(6):492-5. Ann Pathol. 2003. PMID: 15094587 French.
-
Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.Breast J. 2006 Jul-Aug;12(4):294-301. doi: 10.1111/j.1075-122X.2006.00267.x. Breast J. 2006. PMID: 16848838
-
Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes.Cancer. 2006 Aug 1;107(3):467-71. doi: 10.1002/cncr.22069. Cancer. 2006. PMID: 16804924
-
New TNM melanoma staging system: linking biology and natural history to clinical outcomes.Semin Surg Oncol. 2003;21(1):43-52. doi: 10.1002/ssu.10020. Semin Surg Oncol. 2003. PMID: 12923915 Review.
-
Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.J Surg Oncol. 2004 Mar;85(3):102-11. doi: 10.1002/jso.20022. J Surg Oncol. 2004. PMID: 14991881 Review.
Cited by
-
Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy.World J Clin Oncol. 2016 Apr 10;7(2):243-52. doi: 10.5306/wjco.v7.i2.243. World J Clin Oncol. 2016. PMID: 27081647 Free PMC article. Review.
-
Electrons for intraoperative radiotherapy in selected breast-cancer patients: late results of the Montpellier phase II trial.Radiat Oncol. 2013 Aug 1;8:191. doi: 10.1186/1748-717X-8-191. Radiat Oncol. 2013. PMID: 23902825 Free PMC article. Clinical Trial.
-
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.Med Oncol. 2014 Oct;31(10):163. doi: 10.1007/s12032-014-0163-9. Epub 2014 Sep 4. Med Oncol. 2014. PMID: 25186065 Clinical Trial.
-
Behaviour of breast cancer molecular subtypes through tumour progression.Clin Transl Oncol. 2012 Jun;14(6):481-5. doi: 10.1007/s12094-012-0827-x. Clin Transl Oncol. 2012. PMID: 22634538
-
The role of tumor hypoxia in MUC1-positive breast carcinomas.Virchows Arch. 2011 Oct;459(4):367-75. doi: 10.1007/s00428-011-1142-6. Epub 2011 Sep 3. Virchows Arch. 2011. PMID: 21892751
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical